Practical implementation of Bayesian decision making is hindered by the fact that optimal decisions may be sensitive to the model inputs: the prior, the likelihood and/or the underlying utility function. Given the structure of a problem, the analyst has to decide which sensitivity measures are relevant and compute them efficiently. We address the issue of robustness of the optimal action in a decision making problem with respect to the prior model and the utility function. We discuss some general principles and apply novel computational strategies in the context of two relatively complex medical decision making problems.
Introduction
Bayesian decision theory describes a decision making problem through a set of feasible alternatives, a ∈ A; a set of states or parameters, θ ∈ Θ; a prior distribution, π(θ); a likelihood, l(x|θ); and a utility function, u (a, θ, x) . Usually, the utility function does not depend on the data x. In such cases, we write
u(a, θ).
The optimal decision a * is the alternative that maximizes the posterior expected utility:
In some cases, the interest focuses on finding an optimal decision before observing data, changing (2) to:
Among many reviews of Bayesian decision theory see, for example, [1] [2] [3] .
Practical implementation of (1) is hindered by the fact that U (a) and, hence, the optimal action a * could be sensitive to the chosen prior π(·), likelihood
l(·|·) and/or utility function u(·).
A skeptical decision maker will require, in addition to the optimal solution, some description of its robustness with respect to reasonable changes and imprecisions in the specification of inputs.
Moreover, the resolution of (1) must frequently be performed by simulationbased methods, mainly by Markov chain Monte Carlo (MCMC) ones. In these cases, robust analyses may become very involved computationally.
Reviews of this area are provided in [4] [5] [6] . Most authors, see e.g. [4, 7] , focus on prior robustness. Sensitivity with respect to the prior and the likelihood is studied in [8, 9] . Sensitivity with respect to the loss function is considered in [10, 11] . Joint sensitivity with respect to the utility function and the prior is investigated in [12] . Discussions concerning applications to medical models, as the ones we shall pursue here, may be found in [7, 13, 14] .
In this paper, we address the robustness of the optimal action in a decision making problem with respect to the prior model or the utility function. We discuss several general principles and apply new computational strategies in the context of two relatively complex medical decision making problems. The outline of the paper is as follows. In Section 2, we discuss some general principles and new computational strategies to address a robust analysis with respect to the prior distribution or the utility function. Some theoretical results are provided. In Section 3, the proposed robustness analysis is applied to two medical decision making problems, that are representative of a wide range of applications in that area. Section 4 provides conclusions. An Appendix includes proofs of the theoretical results. We emphasize that the developed methodology is potentially applicable to many decision making problems and not just to those described through this paper.
Bayesian robustness approach
In this section, U (a) is represented as U (a; u, π) because of the dependence relationship. Two key sensitivity aspects (see, for example, [15] ) in a decision making problem are:
1. Expected utility sensitivity. Changes in the expected utility of a * as a function of (u, π). It should be, therefore, undertaken a study of the operator: 
which expresses differences in expected utility between a * and b when (u, π) changes;
which expresses how the optimal alternative changes as (u, π) changes, and
which expresses maximum differences in expected utility between a * and the set of alternatives b ∈ A, as (u, π) changes. When the value of this operator is 0, a * remains optimal for any (u, π).
In this paper, we focus on sensitivity with respect to the prior distribution, by considering the operator given in (3), and the operators given by (4)- (5) when the utility function changes.
Sensitivity with respect to the prior distribution
Many papers on Bayesian robustness have studied this question only focusing on changes in the prior distribution π, allowing π to range in various classes Γ of probability distributions. See, for example, [4, 5, 16, 17] and references therein.
In order to quantify local sensitivity with respect to prior changes, [18] proposed to consider the derivativeU π of U with respect to π (given a and u), defined as the linear operator such that:
where h is a 0 mass signed measure, and h is the bounded variation norm:
When the decision problem does not include data to update the prior distri-
as a rate of change of the expected utility if we change the prior probability measure from π to π + h. The use of such derivatives in robust Bayesian analysis is reported, among others, in [19] [20] [21] [22] .
Here, we consider changes in expected utility when varying the prior π. Hence, in the following discussion, the decision a * and the utility u are fixed, and we denote U (π) = U (a * ; u, π). The practical impact of the computed prior sensitivity measure would be the following: large values suggest the decision maker that any conclusion should not be applicable to values (u, π) far apart from the initial ones. A more careful prior elicitation might be in order. On the other hand, low values imply that the conclusions can be considered reasonably robust against changes in the prior probability.
Assume that the information about the probability distribution allows us to constrain it to a convex class Γ. Starting with a particular prior probability model π ∈ Γ, we study the impact of changes in π on the expected utility of a *
. We use neighborhoods Γ ε ⊆ Γ of π defined via ε-contaminations, i.e.:
These neighborhoods are commonly used in sensitivity analysis, see, e.g., [1, 4, 7, 11] .
For a given π and a given neighborhood Γ ε of alternative prior models π around π, the following sensitivity measure is defined in [21] :
Note that this supremum is an upper bound on the changes in expected utility when varying the prior model infinitesimally in this class as:
whereU π is the derivative of U with respect to π evaluated at δ = π − π. Due to the fact that π − π ≤ ε, ∀π ∈ Γ ε , we define an infinitesimal sensitivity measure for the prior distribution π as:
With this definition, we remove dependence on ε. Therefore, this quantity measures the maximum variation.
The remaining problem is how to evaluate that supremum. For the following quantile class Γ Q of probability measures and the ε-contamination neighborhood Γ ε ⊆ Γ Q , Theorem 1 provides an algorithm to compute the supremum through the solution of linear programming problems. The quantile class is given by:
where A 1 , . . . , A n is a measurable partition of Θ with
Theorem 1 When the probability model does not include data, given π ∈ Γ Q
and Γ ε ⊆ Γ Q , then:
where H 1 , H 2 are, respectively, the optimal values of the linear programming problems:
When the probability model contains data, the prior distribution may be updated by Bayes' theorem. In this case, we may compute the derivative by using a result in [18] and the supremum of the derivative can be calculated as in [21] . Concretely, the calculations can be performed by using Theorem 1 and
Sensitivity with respect to the utility function
We now study changes in U (a * ; u, π)−U (b; u, π) as we vary the utility function and the alternative b, i.e., the operators in (4)- (6) are analyzed when both the incumbent optimal decision and the utility change. We focus on a class of utility functions which are typical for a wide range of medical applications, as it is shown in the next section. They include a trade-off between a term related to sampling cost and a term referring to the posterior (predictive)
probability of some event of interest, that we aim at detecting. Interesting issues for Bayesian robustness concerning other utility functions can be found in [23] .
Specifically, assume that the class of utility functions U is composed by functions of the type:
where n a ∈ N is the number of samples under action a, E is an objective event,
1 E is the indicator function for E and r is the ratio between sampling cost and the penalty of underachieving the objective. Then, the expected utility is of the form
where f (a) is the probability of achieving the objective. In Section 3 we illustrate the values with examples.
We study now the impact of the ratio r in the variation of the optimal alternative, through operators (4)- (6) . The first result is immediate.
Proposition 1
The utility functions belonging to U, where r > 0, verify:
Therefore, in order to find out how much r may decrease without changing the optimal decision, we have to consider decisions d such that n a = n a * + k (k ≥ 1). Then, the following result is obtained.
Theorem 2
The parameter r may be decreased as much as ∆r without changing the optimal solution, where
Similarly, we consider decisions a, with n a = n a * − k, (k ≥ 1), to know how much r can be increased without changing the optimal decision. Then, a result analogous to Theorem 2 is:
Theorem 3 The parameter r may be increased as much as ∆r without changing the optimal solution, where
Through this section, we have discussed some general principles and proposed new computational strategies, which we will illustrate with two relatively complex medical decision making problems in the next section. Note that we are using operators (5) and (6), looking for changes in the optimal decision. Moreover, Proposition 1 can be applied to study operator (4). Other important examples of medical decision making problems with similar features include optimal scheduling of chronic diseases ( [24] [25] [26] [27] [28] [29] ) and optimal design for implantable heart defibrillators ( [30] [31] [32] ).
Optimal screening schedules for breast cancer
The problem of optimal screening schedules for a chronic disease as, for example, breast cancer is considered in [27] . The decisions to be made include the age α at which to begin regular screening and the frequency δ of screenings,
i.e., a = (α, δ). A four state semi Markov process to describe the history of a chronic disease is defined in [27, 28, 33] . The four states are "disease is absent or present but not detectable" (A), "detectable pre-clinical" (B), "clinical" (C) and "death"(D).
For breast cancer, the following specifications are used in [27] . Let p denote the transition probability from A to B (1-p is the transition probability from A to D), t 2 is the transition time from A to B, t 3 is the transition time from B to C, and t 4 is the transition time from A to D. Also, t 1 = 1 or t 1 = 0 shows whether a patient's state changes from A to B or from A to D. We denote with θ = (t 1 , t 2 , t 3 , t 4 ) the patients history. For the sake of simplicity, we assume no transitions between B and D are possible. If not detected, every preclinical case develops into a clinical case in t 3 years. Letf 2 (t 2 ) denote the empirical distribution for t 2 based on historical data, and let y be a patient's age, when entering state B. In [27] , it is proposed to use p = 1/8 and m 2 t 2 ) . Figure 1 shows the probability model. Deciding on an optimal screening schedule requires specifying in the utility function the trade-off r between the screening cost and the probability of early breast cancer detection. Let E denote this event. Let n a (θ) be the number of screenings under the state θ and the schedule a. The utility function is given by:
where 1 E (a, θ) is 1 if, for θ, we detect breast cancer early, and 0 otherwise.
For a trade-off parameter r = 0.001, the maximal expected utility is achieved at α * = 42, δ * = 1.96, with value 51.8202. Note that the expected utility value has been scaled by a factor of 1000 in order to avoid numbers of low order of magnitude. We consider uncertainty in the probability model for t 2 and t 3 . By using the previous information, and for illustration purpose, we embed the prior distribution into a quantile class with two classes for t 3 and six classes for t 2 . We then obtain 12 classes, as shown in Table 1 Table 1 Probabilities p i of the partition for the prior distribution.
We computeh j and h j for each element in the partition. We obtain H 1 = and, therefore, m π = 44.3992. We might conclude that there is no robustness in expected utility, since the value m π is large when compared with the value of U (π). This lack of robustness confirms the discussion on optimal screening designs for breastcancer. The expected utility surface is extremely flat in a relatively wide neighborhood of the optimal solution, leaving opportunity for extensive disagreement of the optimal schedule. To further understand the nature of this lack of robustness, we consider a reduced quantile class defined by refining the partition.
In this case:
After observing the values p jhj , it is deduced that the most influential variable is t 3 . Then, we split the intervals for t 3 , as in [34] , becoming now (0, 26 .3005, which is a considerable reduction. The process can be repeated to obtain more reduction in the sensitivity measure by using the expert opinion information.
Optimal apheresis schedules
Optimal apheresis designs for cancer patients undergoing high-dose chemotherapy is considered in [35] . Between a pre-treatment and the start of chemotherapy, stem cells are collected to allow for later reconstitution of white blood cell components. There are two possible treatments. Depending on which one the patient undergoes, the first stem cell collection process (apheresis) is scheduled on the fifth or seventh day after pre-treatment. The problem is to decide for which of the remaining days further aphereses should be scheduled. Clearly, the optimal solution should propose stem cell collections on days with high predicted stem cell concentrations. The prediction is based on observations of stem cell levels (represented by CD34 antigen levels) from past patients. 
where L h is the volume of blood processed at each stem cell collection for the new patient (y ij is recorded per volume unit). The utility function is:
where 1 A is the indicator function for event A, c 1 is the cost of each apheresis, c 2 is the penalty for under-achievement of the target y * and n a is the number of apheresis under alternative a. The decision making problem is then:
where π(θ|y) ∝ l(y|θ)π(θ) is the posterior distribution on the unknown model parameters given the observed data y.
In [35] , (9) is solved for a particular model p(y|θ) based on a rescaled Gamma curve for the mean profile of each patient and a hierarchical prior probability model. A covariate, x i = 1 or x i = 2, records each patient's pre-treatment.
The two pre-treatments define the choice of the prior distribution at the first level. The hyperprior at the second level is common for both pre-treatments.
The model is given by:
Here g(t; e, s) = Γ(t; α, β)/c is the density function of a Gamma distribution with parameters β = e/s . Tables 2 and 3 5th, 6th and 8th -3 Table 2 Top five solutions for patient 24.
By using Theorem 2 for patient 24, we obtain ∆r = 0.09795. Table 3 Top five solutions for patient 25. of r is 0.1, then we can decrease r by 97.95% without changes in the optimal alternative. If we take r = 0.1 − 0.09795, we find that alternatives a 4 and a 5 become optimal. Note that in the original utility function we used c 1 = 1 and We repeat the study for patient 25, obtaining different results. The parameter r can decrease only by 4.08% without changing the optimal solution. Then, alternative a 2 becomes optimal. However, r could be increased by 165%. In this case, the optimal alternative is to collect stem cells on days seventh and ninth, with expected utility equal to -8.91. This alternative is not among the best five ones. The key conclusion is that the optimal solution is robust against increasing changes and sensitive for decreasing changes.
The practical implication is that the one could comfortably recommend collection on days 5th and 6th, and on days 7th, 9th and 10th, respectively for patients 24 and 25. Also a clinician might choose for additional collection on day 11th, if desired, for patient 25. Although the recommendation is based on a formal decision theoretical setup, with a specific probability model and loss function, the conclusion is more general. One particular feature that tradi-tionally prevents many researchers from applying formal decision theoretical approaches in biomedical problems is the need for a specific utility (or loss function). It is often not clear who is the relevant decision maker and whose loss function should be used, how should monetary costs and health benefits be traded off, etc. The proposed study of robustness and sensitivity mitigates some of these concerns and can facilitate increased use of decision theoretical methods in biomedical applications.
Finally, note that the same MCMC outputs obtained to approximate the optimal design have been used in the sensitivity analysis. This type of analysis has a low computational cost (see, for example, [36] ).
Conclusion
The Bayesian approach provides a coherent methodology for decision making 
As we look for the minimum ∆r, we obtain the proposed result. 2
Proof 4 (of Theorem 3) Analogous to the previous proof.
